Bookmark and Share

Rodney J. Taylor
 

Rodney J. Taylor M.D., M.P.H.

Academic Title: Associate Professor
Primary Appointment: Otorhinolaryngology-Head & Neck Surgery
rtaylor@smail.umaryland.edu
Location: JTFB 500
 

Personal History:

Rodney J Taylor MD, MSPH is an associate professor in the Department of Otorhinolaryngology- Head & Neck Surgery at the University of Maryland of School of Medicine (UMSOM). Dr. Taylor is the Director of General Otorhinolaryngology at UMSOM and the Chief of Otolaryngology at the Veteran’s Administration Medical Center at Baltimore. He joined the faculty of the Department of Otorhinolaryngology in 2001. Dr. Taylor has been recognized by local and national organizations as one of 'America’s Top Otolaryngologist.'

Dr. Taylor graduated cum laude from Harvard College in 1991 where he was Senior Class President, Varsity Football player and received the Francis Burr Award for character, leadership, and athletic ability. He then graduated from Harvard Medical School in 1995, receiving his MD, while also serving as Academic advisor and counselor for Harvard College pre-med students. Following medical school, Dr. Taylor spent 6 years at the University of Michigan completing his residency in Otolaryngology- Head & Neck Surgery. While at the University of Michigan, he spent a year developing novel techniques in head and neck cancer surgery, as well as developed and studied Quality of Life instruments among head and neck cancer patients. Dr. Taylor also received his Master from the University of Michigan School of Public Health in 1999.

Research Interests:

Dr. Taylor is the Associate Chair of Research in the Department of Otolaryngology-Head & Neck Surgery. He oversees more than 20-full time personnel in a laboratory with multiple grants including 6 NIH/federal grants. Dr. Taylor’s lab has focused on factors impacting immuno-cytotoxicity and immune-tolerance using cancer cell lines and mouse tumor models. Based upon findings from his laboratory, he initiated and completed a multi-institutional clinical trial evaluating the impact of Natural Killer cells receptor polymorphisms on antibody-based therapy for HNC. This work has provided insight into which patient best benefit from antibody-based therapy for SCCHN. His lab currently collaborates with Dr. Zalzman’s lab and he has successfully established mouse models to study head and neck cancer cell immortality mechanisms and behavior using xenografts.


Clinical Specialty:

Dr. Taylor specialties include Head and Neck Surgical Oncology, Rhinology and Sinus disease, Endocrine Surgery (thyroid and parathyroid), Sleep apnea, and Robotic Surgery.


Publications:

Selected Publications:

Taylor RJ, Chepeha J, Teknos TN, Bradford CR, Sharma PK, Terrell JE, Wolf GT, Chepeha DB. Functional shoulder assessment after modified radical and selective neck dissection. Head Neck. 2002 May; 24(5):432-6.

Taylor RJ, Chepeha J, Teknos TN, Bradford CR, Sharma PK, Terrell JE, Hogikyan ND, Wolf GT, Chepeha DB. Development and validation of the Neck Dissection Impairment Index (NDII) - a quality of life measure. Archives of Otolaryngology - Head and Neck Surgery 2002 Jan;128:44-49.

Taylor RJ, Wahl R, Sharma PK, Bradford CR, Terrell JE, Teknos TN, Wolf GT, Chepeha DB. Sentinel node localization for oral cavity and oropharyngeal squamous cell carcinoma. Archives of Otolaryngology -- Head & Neck Surgery. 127(8):970-4, 2001 Aug.

Taylor RJ, Chiu AG, Palmer JN, MD; Schofield K, O’Malley BW Jr., Wolf J, Informed Consent in Sinus Surgery: Link between Demographics and Patient Desires, Laryngoscop.115: 826-831, 2005.

Masayesva BG,  Mambo E,  Taylor RJ, Goloubeva OG, Zhou S, Cohen Y, Minhas K, Koch W, Sciubba J, Alberg AJ, Sidransky D, Califano J, Mitochondrial DNA Content Increase in Response to Cigarette Smoking, Cancer Epidemiol Biomarkers and Prev 15(1)19-24, 2006

Zafereo ME, Taylor RJ , Pereira KD. Supraglottoplasty for Laryngomalacia with Obstructive Sleep Apnea. Layrngosocpe 118: 2008

Taylor RJ, Chan SL, Wood A, Voskens C, Wolf JS, Lin W, Chapoval A, Schulze D, Strome SE, Fc¿RIIIa Polymorphisms and Cetuximab Induced Cytotoxicity in Squamous Carcinoma of the Head and Neck, Cancer Immunol Immunothre, 2008.

Settle K, Taylor RJ, Wolf J, Young K, Cullen KJ, Carter K, Ord R, Zimrin A, Strome SE, Suntharalingam M. Race Impacts Outcome in Stage III/IV Squamous Cell Carcinomas of the Head & Neck Following Concurrent Chemoradiation Therapy,. Cancer, April 15, 2009.

Yovino S, Taylor R, Wolf J, Cullen K, Zimrin A, Strome S, Regine W, Suntharalingam M: Primary Tumor Volume Is an Important Predictor of Clinical Outcomes Among Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck Treated With Definitive Chemoradiotherapy.Int. J. Radiation Oncology Biol. Phys., 2011.

Ambro B, Goodstein L, Morales R, Taylor R. Evaluation of Superficial Musculoaponeurotic System Flap and Fat Graft Outcomes for Benign and Malignant Disease, OHNS  June 2013.

Taylor RJ, Saloura V, Jain A, Goloubeva O, Wong R, Krongsberg S, Silpino L, de Souza J, Madhavi N, Seiwert T, Vokes E, Villaflor V, Strome SE, Cohen, EW. Phase II study of cetuximab and lenalidomide in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Can Res 2015.